Enasidenib is a small molecule inhibitor of Isocitrate Dehydrogenase 2 (IDH2) which is approved as monotherapy in patients with R/R IDH2-mutated AML based on studies demonstrating a favorable response rate and favorable OS in this setting (7, 8). Here, IDH2 is linked to acute myeloid leukemia.